Shared Decision Making for Choosing Autosomal DOminant Polycystic Kidney Disease Treatment
Clinical Trial for Shared Decision Making Model for Choosing Pharmacotherapy in ADPKD Patients
Seoul National University Hospital
340 participants
Oct 21, 2024
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to generate clinical evidence and assess the feasibility of a shared decision-making (SDM) model for the selection of Tolvaptan in patients with ADPKD.
Eligibility
Inclusion Criteria5
- Participants between the age of 18 to 80
- Participants with a diagnosis with CKD stage 2 or 3
- Participants with a diagnosis with ADPKD classified as 1C, 1D, or 1E according to Mayo classification
- Participants with the ability to communicate and use digital devices
- Participants with no severe visual impairment and cognitive dysfunction
Exclusion Criteria3
- Participants who were previously exposured to tolvaptan
- Participants who are contraindicated to tolvaptan
- Participants who were judged ineligible by the investigator
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Shared decision making model for choosing pharmacotherapy in ADPKD patients. This newly developed shared decision making model follows the SHARE approach and includes patient education, identifying values and preferences, reaching a decision and evaluating.
Usual care for ADPKD patients
Locations(9)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06618638